Incyte Co. (INCY) Price Target Cut to $145.00 by Analysts at SunTrust Banks, Inc.
Incyte Co. (NASDAQ:INCY) had its target price reduced by SunTrust Banks, Inc. from $160.00 to $145.00 in a research report issued to clients and investors on Wednesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. SunTrust Banks, Inc.’s price target would suggest a potential upside of 17.78% from the stock’s previous close.
Several other analysts have also recently issued reports on INCY. Raymond James Financial, Inc. cut shares of Incyte from an “outperform” rating to a “hold” rating in a research note on Thursday, April 6th. Zacks Investment Research raised shares of Incyte from a “sell” rating to a “hold” rating in a research note on Tuesday. Gabelli began coverage on shares of Incyte in a research note on Monday, April 10th. They set a “buy” rating and a $185.00 price objective for the company. BMO Capital Markets reissued an “outperform” rating and set a $149.00 price objective (up from $135.00) on shares of Incyte in a research note on Thursday, February 16th. Finally, Barclays PLC lowered their price objective on shares of Incyte from $185.00 to $180.00 and set an “overweight” rating for the company in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $139.40.
Incyte (NASDAQ:INCY) traded down 1.15% during midday trading on Wednesday, hitting $123.11. The stock had a trading volume of 2,034,400 shares. The firm has a market cap of $23.32 billion, a P/E ratio of 227.98 and a beta of 0.78. Incyte has a 12-month low of $68.03 and a 12-month high of $153.15. The stock has a 50-day moving average price of $139.05 and a 200 day moving average price of $114.33.
Incyte (NASDAQ:INCY) last announced its quarterly earnings data on Tuesday, February 14th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.14 by $0.09. Incyte had a net margin of 14.71% and a return on equity of 50.38%. The company had revenue of $326 million for the quarter, compared to analysts’ expectations of $324.90 million. During the same period in the prior year, the firm earned $0.29 earnings per share. The firm’s quarterly revenue was up 33.9% on a year-over-year basis. On average, equities analysts anticipate that Incyte will post $0.18 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/incyte-co-incy-receives-buy-rating-from-suntrust-banks-inc/1205265.html.
In other news, EVP Steven H. Stein sold 32,000 shares of the company’s stock in a transaction dated Friday, April 7th. The shares were sold at an average price of $137.88, for a total value of $4,412,160.00. Following the sale, the executive vice president now owns 41,648 shares in the company, valued at approximately $5,742,426.24. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Paul A. Friedman sold 50,000 shares of the company’s stock in a transaction dated Friday, March 17th. The shares were sold at an average price of $148.72, for a total transaction of $7,436,000.00. Following the completion of the sale, the director now owns 302,976 shares in the company, valued at approximately $45,058,590.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 127,571 shares of company stock worth $18,145,772. Company insiders own 13.70% of the company’s stock.
Large investors have recently modified their holdings of the stock. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Incyte by 1.7% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,322 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 22 shares during the period. Seven Bridges Advisors LLC raised its stake in shares of Incyte by 27.1% in the third quarter. Seven Bridges Advisors LLC now owns 1,867 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 398 shares during the period. Douglass Winthrop Advisors LLC bought a new stake in shares of Incyte during the first quarter worth about $201,000. Pinnacle Associates Ltd. bought a new stake in shares of Incyte during the fourth quarter worth about $212,000. Finally, IFM Investors Pty Ltd bought a new stake in shares of Incyte during the fourth quarter worth about $214,000. Institutional investors and hedge funds own 92.62% of the company’s stock.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.